There have been comments in some quarters that Amgen's move into making its own biosimilars -- the biotech version of generics -- is somehow self-contradictory. Up until this announcement, Amgen has been focusing on defending their superior position by indicating how difficult it is to manufacture biologics and how consumers ought not to trust biosimilars: